Food & Beverages company Manorama Industries announced Q4FY25 & FY25 results Q4FY25 Financial Highlights: Revenues during Q4FY25 grew by 80% YoY to Rs 2,328 million due to higher demand of the Company's product portfolio coupled with commercialization of the new fractionation capacity. EBITDA during Q4FY25 surged by 208% YoY at Rs 639 million; EBITDA margin for the quarter expanded by 1,139 bps YoY to 27.5% reflecting the management's robust cost management strategies coupled with operating leverage. PAT during Q4FY25 increased by 238% YoY to Rs 423 million; PAT margin expanded by 849 bps to 18.2% in Q4FY25. FY25 Financial Highlights: Revenues during FY25 grew by 69% YoY to Rs 7,708 million owing to sustained higher demand of the Company's overall product portfolio. EBITDA during FY25 surged by 160% YoY at Rs 1,911 million; EBITDA margin for the year expanded by 870 bps YoY to 24.8%. PAT during FY25 increased by 179% YoY to Rs 1,121 million; PAT margin expanded by 576 bps to 14.5% in FY25. Ashish Saraf, Chairman and Managing Director of Manorama Industries, said: "We are pleased to announce that the Company has achieved its highest quarterly and full year operational performance during Q4 and FY25, driven by strong market demand for our wide variety of speciality butters and fats, along with increased volumes from the commissioning of the new fractionation capacity. We have surpassed our financial guidance for FY25, registering a topline of Rs 771 crore with a robust growth 69% YoY along with improved profitability. The domestic to export mix stood at 27:73 in FY25. Additionally, the Company has announced a final dividend of Rs 0.60 paise per share (30% of face value of Rs 2 per share) for its shareholders. We specialize in developing several innovative food ingredients including cocoa butter equivalents (CBEs) for chocolate, coating, and molding applications. By leveraging our expertise, we address the increasing global demand and provide tailored solutions that foster success for our partners in the food and personal care industry. We have achieved significant advancements in extraction technology, expanded our product offerings, and created strategic global subsidiaries in Africa, UAE and Brazil to enhance our market position. We expect to gain momentum in operational efficiencies and cost rationalisation with improvement in capacity utilisation of our new fractionation capacity in FY26. We anticipate to report a revenue of Rs 1,050+ crore in the FY26.. During the financial year 2021-25 period our revenue, EBITDA and PAT has registered CAGR of 40%, 53% and 66%, respectively. We emphasize ethical practices and environmental responsibility, aligning with ESG objectives while upholding rigorous standards of traceability and sustainability. Our ongoing investment in R&D; will drive innovation and meet our customers' evolving needs, positioning us for long-term success and thus, deliver value for our esteemed stakeholders." Result PDF